The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 11, 2023
Filed:
Dec. 30, 2020
Applicants:
Ilias Biologics Inc, Daejeon, KR;
Ilias Therapeutics, Inc., New York, NY (US);
Inventors:
Assignees:
ILIAS Biologics Inc., Daejeon, KR;
ILIAS Therapeutics, Inc., New York, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/12 (2015.01); A61K 38/17 (2006.01); A61K 47/69 (2017.01); A61P 15/06 (2006.01); A61K 38/095 (2019.01); A61K 9/127 (2006.01); A61K 31/137 (2006.01); A61K 31/4025 (2006.01); A61K 31/405 (2006.01); A61K 31/43 (2006.01); A61K 31/4422 (2006.01); A61K 31/545 (2006.01); A61K 31/57 (2006.01); A61K 31/7048 (2006.01); A61K 33/06 (2006.01); A61K 38/16 (2006.01); A61K 38/45 (2006.01); A61K 38/51 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1738 (2013.01); A61K 9/127 (2013.01); A61K 31/137 (2013.01); A61K 31/405 (2013.01); A61K 31/4025 (2013.01); A61K 31/43 (2013.01); A61K 31/4422 (2013.01); A61K 31/545 (2013.01); A61K 31/57 (2013.01); A61K 31/7048 (2013.01); A61K 33/06 (2013.01); A61K 38/095 (2019.01); A61K 38/164 (2013.01); A61K 38/168 (2013.01); A61K 38/1709 (2013.01); A61K 38/1774 (2013.01); A61K 38/45 (2013.01); A61K 38/51 (2013.01); A61K 47/6911 (2017.08); A61P 15/06 (2018.01);
Abstract
The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.